Chronic pulmonary hypertension is a serious complication of a number of chronic lung and
heart diseases. In addition to vasoconstriction, its pathogenesis includes injury to the …

Life-threatening increases in pulmonary vascular resistance have been noted on acute
withdrawal of inhaled nitric oxide (NO), although the mechanisms remain unknown. In vitro …

This article briefly reviews the background of endothelium-dependent vasorelaxation,
describes the nitric oxide/cGMP/protein kinase pathway and its role in modulating …

The purpose of this study was to investigate whether a membrane‐permeable superoxide
dismutase mimetic, tempol, added either alone or in combination with the nitric oxide (NO) …

The homeostasis of nitric oxide (NO) is attained through a balance between its production
and consumption. Shifts in NO bioavailability have been linked to a variety of diseases …

Objective Inhaled nitric oxide (iNO) is front-line therapy for pulmonary hypertension after
repair of congenital heart disease. However, little clinical data exists regarding the effects of …

Inhaled nitric oxide gas (iNO) vasodilates the pulmonary circulation. The effective “dose” of
iNO for chronic treatment of pulmonary hypertension is unknown. Increased abundance of …

Inhaled nitric oxide allows selective pulmonary vasodilatation with rapidity of action. It is
effective in the acute post-operative management of pulmonary hypertension in cardiac …

The availability of inhibitors of cGMP‐specific phosphodiesterase 5 (PDE 5), such as
sildenafil, has revolutionized the treatment of pulmonary hypertension (PH). Sildenafil may …